MARKET

DFTX

DFTX

Definium Therapeutics
NASDAQ
16.90
+0.65
+4.00%
Closed 19:58 02/06 EST
OPEN
16.49
PREV CLOSE
16.25
HIGH
17.02
LOW
16.46
VOLUME
1.17M
TURNOVER
0
52 WEEK HIGH
18.70
52 WEEK LOW
4.700
MARKET CAP
1.66B
P/E (TTM)
-8.5704
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DFTX last week (0202-0206)?
Weekly Report · 1h ago
Psychedelic: Analyst initiates Definium, Helus with Buy ratings
TipRanks · 3d ago
Is Adsett’s Board Appointment And Breakthrough DT120 Status Altering The Investment Case For Definium Therapeutics (DFTX)?
Simply Wall St · 4d ago
A Look At Definium Therapeutics (DFTX) Valuation After Analyst Coverage And FDA Breakthrough Therapy Designation
Simply Wall St · 5d ago
LSD therapy biotech Definium sued for alleged trade secret theft 
Reuters · 6d ago
Definium Therapeutics Grants Stock Options to New Employees
Reuters · 6d ago
Weekly Report: what happened at DFTX last week (0126-0130)?
Weekly Report · 02/02 10:03
Definium Therapeutics Adds Commercial Leader As Phase 3 Milestones Approach
Simply Wall St · 01/31 03:40
More
About DFTX
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Webull offers Definium Therapeutics Inc stock information, including NASDAQ: DFTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DFTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DFTX stock methods without spending real money on the virtual paper trading platform.